These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37708254)

  • 1. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
    King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
    Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
    Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
    JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
    N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
    Senna MM; Kwon O; Piraccini BM; Sinclair R; Ball S; Ding Y; Chen YF; Dutronc Y; King B
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3209-3220. PubMed ID: 37991697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
    Craiglow B; Lee YW; Vañó-Galván S; Egeberg A; Dutronc Y; Durand F; Pierce E; Yu G; Chen YF; Mostaghimi A
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1959-1968. PubMed ID: 38904749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
    Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
    J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
    Taylor S; Korman NJ; Tsai TF; Shimomura Y; Feely M; Dutronc Y; Wu WS; Somani N; Tosti A
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3181-3191. PubMed ID: 37740856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    King B; Ko J; Kwon O; Vañó-Galván S; Piraccini BM; Dutronc Y; Yu G; Liu C; Somani N; Ball S; Mesinkovska NA
    JAMA Dermatol; 2024 Aug; ():. PubMed ID: 39141364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
    Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
    J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Baricitinib in the Treatment of Alopecia Areata.
    Singh R; Driscoll MS
    J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
    Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.
    Fang H; Zhang F; Lin W; Jiang Y; Liu Q; Yang D
    Front Immunol; 2024; 15():1395288. PubMed ID: 38903518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.
    Tang GT; Triwongwaranat D; Sinclair R; Joseph S; Eisman S; Rathnayake D; Varathan V; Trindade de Carvalho L; Bhoyrul B
    Clin Exp Dermatol; 2024 Jul; 49(8):875-878. PubMed ID: 38270233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
    Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib for the Treatment of Alopecia Areata.
    Freitas E; Guttman-Yassky E; Torres T
    Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.